Table 1.

Demographic and clinical variables of the cohort

Patient IDSexAge, yMS subtypeDuration, yEDSSPrevious DMDConcomitant DMDHLA DRB1
MS01F48SPMS14.795.0MPNA*0101*0301
MS02F50SPMS9.676.0IFN-β1a s.c.NANA
MS03M27PPMS6.66.0GANANA
MS04F57PPMS4.295.5NANA*1501*1301
MS05M40SPMS8.186.5GA, IFN-β1a s.c.NA*0701*1001
MS06M57SPMS29.296.0IFN-β1a i.m.NA*1104*1301
IFN-β1a s.c.
MS07F56PPMS7.466.5NANA*0102*0404
MS08M59RRMS1.816.0GANA*0101*1101
NMO01M38NA3.373.5AZA, RTX, IFN-β1a s.c.RTX*03*13
NMO02F39NA21.916.0AZA, RTX, PDN, IVIG, MTXMMFNA
NMO03F40NA3.224.5RTX, MPRTX*0404*1001
NMO04F43NA8.475.0RTX, CP, CyA, IVIG, MPRTX*0301*1101
  • AZA, azathioprine; CP, cyclophosphamide; CyA, cyclosporine A; F, female; GA, glatiramer acetate; IVIG, i.v. immunoglobulins; M, male; MMF, mycophenolate mofetil; MP, methylprednisolone; MTX, mitoxantrone; NA, not available; PDN, prednisone; PPMS, primary-progressive multiple sclerosis; RRMS, relapsing-remitting multiple sclerosis; RTX, rituximab; SPMS, secondary-progressive multiple sclerosis.